Clinical Sciences - Clinical Trials of Antiretroviral Therapeutic Strategies

110 - CTN 164– A PROSPECTIVE RANDOMIZED TRIAL OF STRUCTURED TREATMENT INTERRUPTION (STI) VERSUS IMMEDIATE SWITCHING (IS) IN HIV-INFECTED PATIENTS (PTS) EXPERIENCING VIROLOGIC FAILURE ON HAART

111 - PREDICTORS OF VIROLOGIC SUCCESS IN PATIENTS RANDOMIZED TO A STRUCTURED TREATMENT INTERRUPTION OR IMMEDIATE SWITCH TO SALVAGE ANTIRETROVIRAL THERAPY, CTN 164

112 - RESULTS OF SIMPLIFIED PROTEASE INHIBITOR TRIAL (SPRINT): ANTIVIRAL EFFECT OF ONCE DAILY SAQUINAVIR SGC PLUS RITONAVIR (SQV/r) VS TWICE DAILY INDINAVIR PLUS RITONAVIR (IDV/r)

113 - RANDOMIZED CONTROLLED TRIAL OF ONCE DAILY (QD) TENOFOVIR (TDF), 3TC AND LOPINAVIR/RITONAVIR (LPV/r) VERSUS REMAINING ON THE SAME REGIMEN IN HIV-INFECTED PATIENTS VIROLOGICALLY SUPPRESSED ON THEIR FIRST PI-CONTAINING HAART REGIMEN

114 - VALIDATION OF INITIAL PLASMA VIREMIA RESPONSE TO SALVAGE THERAPY FOR AIDS WITH MULTI-DRUG RESISTANT HIV AS A SURROGATE MARKER OF CLINICAL EFFICACY IN THE OPTIMA TRIAL

115 - THE IMPACT OF AIDS-DEFINING EVENTS AND SERIOUS ADVERSE EVENTS (SAE) IN PATIENTS WITH ADVANCED HIV DISEASE IN THE OPTIMA TRIAL: WHAT AFFECTS PATIENTS' QUALITY OF LIFE MOST?